Interleukin receptor antagonist induction in kidney transplantation: Is it worth the price?
作者信息
Kher V
机构信息
Chairman, Division of Nephrology and Renal Transplant Medicine, Medanta Kidney and Urology Institute, Medanta - The Medicity, Gurgaon, Haryana, India.
出版信息
Indian J Nephrol. 2013 Nov;23(6):413-4.
Abstract
摘要
相似文献
1
Interleukin receptor antagonist induction in kidney transplantation: Is it worth the price?
Indian J Nephrol. 2013 Nov;23(6):413-4.
2
Treatment with an interleukin-1 receptor antagonist protein prolongs mouse islet allograft survival.
Diabetes. 1993 Dec;42(12):1845-51. doi: 10.2337/diab.42.12.1845.
3
Initial clinical experience with interleukin-2 receptor antagonist induction in combination with tacrolimus, mycophenolate mofetil and steroids in simultaneous kidney-pancreas transplantation.
Transpl Int. 2001 Dec;14(6):396-404. doi: 10.1007/s001470100005.
4
Prospective randomized controlled trial of rabbit antithymocyte globulin compared with IL-2 receptor antagonist induction therapy in kidney transplantation.
Ann Surg. 2014 May;259(5):888-93. doi: 10.1097/SLA.0000000000000496.
5
Utility or futility of Interleukin 2 receptor antagonist (IL2RA) induction in kidney transplants-the devil is in the detail.
Transpl Int. 2019 Aug;32(8):794-796. doi: 10.1111/tri.13440.
6
Interleukin-2 receptor antagonist compared with antithymocyte globulin induction therapy in kidney transplantation from donors after cardiac death.
Int J Clin Pract Suppl. 2015 May(183):23-8. doi: 10.1111/ijcp.12663.
7
Compensation for kidney donation: a price worth paying.
Isr Med Assoc J. 2002 Dec;4(12):1139-40.
8
Interleukin-1 receptor antagonist therapy and induction of anterior chamber-associated immune deviation-type tolerance after corneal transplantation.
Invest Ophthalmol Vis Sci. 2000 Dec;41(13):4203-8.
9
The efficacy of interleukin-1 antagonist drugs in combination with colchicine in patients with FMF-AA with colchicine resistance after kidney transplantation: A study with histopathologic evidence.
Clin Transplant. 2021 Jun;35(6):e14309. doi: 10.1111/ctr.14309. Epub 2021 Apr 13.
10
Immunohistochemical localization of interleukin-1beta, interleukin-1 receptor antagonist and interleukin-1beta converting enzyme/caspase-1 in the rat brain after peripheral administration of kainic acid.
Neuroscience. 1999;93(3):915-30. doi: 10.1016/s0306-4522(99)00178-5.
本文引用的文献
1
Efficacy of basiliximab induction in poorly matched living donor renal transplantation.
Indian J Nephrol. 2013 Nov;23(6):409-12. doi: 10.4103/0971-4065.120332.
2
The impact of IL2ra induction therapy in kidney transplantation using tacrolimus- and mycophenolate-based immunosuppression.
Transplantation. 2010 Sep 27;90(6):639-44. doi: 10.1097/TP.0b013e3181ea6788.
3
Interleukin 2 receptor antagonists for kidney transplant recipients.
Cochrane Database Syst Rev. 2010 Jan 20;2010(1):CD003897. doi: 10.1002/14651858.CD003897.pub3.
4
KDIGO clinical practice guideline for the care of kidney transplant recipients.
Am J Transplant. 2009 Nov;9 Suppl 3:S1-155. doi: 10.1111/j.1600-6143.2009.02834.x.
5
Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial.
Am J Transplant. 2009 Jul;9(7):1607-19. doi: 10.1111/j.1600-6143.2009.02668.x. Epub 2009 May 20.
6
Reduced exposure to calcineurin inhibitors in renal transplantation.
N Engl J Med. 2007 Dec 20;357(25):2562-75. doi: 10.1056/NEJMoa067411.
7
Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials.
Transplantation. 2004 Jan 27;77(2):166-76. doi: 10.1097/01.TP.0000109643.32659.C4.
8
Basiliximab widens the therapeutic window for AUC-monitored neoral therapy early after kidney transplantation.
Transplant Proc. 2003 Nov;35(7):2409-11. doi: 10.1016/j.transproceed.2003.08.005.
9
Economic implications of the use of basiliximab in addition to triple immunosuppressive therapy in renal allograft recipients: a UK perspective.
Pharmacoeconomics. 2003;21(2):129-38. doi: 10.2165/00019053-200321020-00005.
10
A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients.
Transplantation. 2001 Oct 15;72(7):1261-7. doi: 10.1097/00007890-200110150-00014.
Zotero 插件